US6458772B1
(en)
|
1909-10-07 |
2002-10-01 |
Medivir Ab |
Prodrugs
|
GB8725939D0
(en)
*
|
1987-11-05 |
1987-12-09 |
Wellcome Found |
Therapeutic compounds
|
GB8829571D0
(en)
*
|
1988-12-19 |
1989-02-08 |
Wellcome Found |
Antiviral compounds
|
US5677308A
(en)
*
|
1996-12-19 |
1997-10-14 |
Lerner; A. Martin |
Method for alleviating spasmodic torticollis
|
US6537997B1
(en)
|
1997-02-18 |
2003-03-25 |
A. Martin Lerner |
Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
|
US6399622B1
(en)
|
1997-02-18 |
2002-06-04 |
A. Martin Lerner |
Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
|
US5872123A
(en)
*
|
1997-02-18 |
1999-02-16 |
Lerner; A. Martin |
Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
|
DE69829784T2
(de)
*
|
1997-08-15 |
2006-02-16 |
Medivir Ab |
3'-Fluorierte Guanosinderivate zur Behandlung oder Prophylaxe von HBV- oder retroviralen Infektionen
|
US20020128301A1
(en)
*
|
1998-02-13 |
2002-09-12 |
Medivir AB |
Non-nucleoside reverse transcriptase inhibitors
|
US6444652B1
(en)
*
|
1998-08-10 |
2002-09-03 |
Novirio Pharmaceuticals Limited |
β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
|
ES2255295T3
(es)
*
|
1998-08-10 |
2006-06-16 |
Idenix (Cayman) Limited |
2'-deoxi-beta-l-nucleosidos para el tratamiento de la hepatitis b.
|
US6107303A
(en)
*
|
1999-03-15 |
2000-08-22 |
Demarco; Charlene C. |
Treatment of Epstein Barr infection
|
US6448256B1
(en)
|
1999-05-24 |
2002-09-10 |
University Of Massachusetts |
Antibiotic prodrugs
|
GB0010446D0
(en)
*
|
2000-04-28 |
2000-06-14 |
Glaxo Wellcome Kk |
Pharmaceutical formulation
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
EP1736478B1
(de)
*
|
2000-05-26 |
2015-07-22 |
IDENIX Pharmaceuticals, Inc. |
Verfahren und Zusammensetzungen zur Behandlung von Flaviviren und Pestiviren
|
US6787526B1
(en)
|
2000-05-26 |
2004-09-07 |
Idenix Pharmaceuticals, Inc. |
Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
|
US6875751B2
(en)
*
|
2000-06-15 |
2005-04-05 |
Idenix Pharmaceuticals, Inc. |
3′-prodrugs of 2′-deoxy-β-L-nucleosides
|
WO2003079972A2
(en)
|
2002-02-22 |
2003-10-02 |
New River Parmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
US20030212051A1
(en)
*
|
2001-04-06 |
2003-11-13 |
Polli James E |
Bile acid containing prodrugs with enhanced bioavailabilty
|
WO2003022209A2
(en)
*
|
2001-09-07 |
2003-03-20 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of valacyclovir hydrochloride
|
JP2005504087A
(ja)
*
|
2001-09-28 |
2005-02-10 |
イデニクス(ケイマン)リミテツド |
4’が修飾されたヌクレオシドを使用するc型肝炎ウイルス治療のための方法および組成物
|
EP1453834A1
(de)
*
|
2001-11-05 |
2004-09-08 |
Glaxo Group Limited |
Wasserfreie kristallform von valaciclovir-hydrochlorid
|
US6849737B2
(en)
|
2001-11-14 |
2005-02-01 |
Teva Pharmaceutical Industries Ltd. |
Synthesis and purification of valacyclovir
|
CA2470255C
(en)
*
|
2001-12-14 |
2012-01-17 |
Kyoichi A. Watanabe |
N4-acylcytosine nucleosides for treatment of viral infections
|
AU2002360697B2
(en)
*
|
2001-12-20 |
2009-04-23 |
Beth Israel Deaconess Medical Center |
Treatment of EBV and KHSV infection and associated abnormal cellular proliferation
|
SE521676C2
(sv)
*
|
2002-01-02 |
2003-11-25 |
Dilafor Ab |
Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
|
BR0307712A
(pt)
*
|
2002-02-14 |
2005-05-24 |
Pharmasset Ltd |
Composto, composição e uso dos mesmos no tratamento de infecções por flaviviridae e proliferação celular anormal
|
WO2004000265A2
(en)
*
|
2002-06-24 |
2003-12-31 |
Ranbaxy Laboratories Limited |
Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
|
AU2003263412A1
(en)
|
2002-06-28 |
2004-01-19 |
Centre National De La Recherche Scientifique (Cnrs) |
1'-, 2'- and 3'- modified nucleoside derivatives for treating flaviviridae infections
|
CN101172993A
(zh)
|
2002-06-28 |
2008-05-07 |
埃迪尼克斯(开曼)有限公司 |
用于治疗黄病毒感染的2′-c-甲基-3′-o-l-缬氨酸酯核糖呋喃基胞苷
|
AU2003247084B9
(en)
|
2002-06-28 |
2018-07-26 |
Centre National De La Recherche Scientifique |
Modified 2' and 3'-nucleoside prodrugs for treating flaviridae infections
|
MXPA04012802A
(es)
*
|
2002-06-28 |
2005-04-19 |
Idenix Cayman Ltd |
Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae.
|
US7608600B2
(en)
*
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
TWI244393B
(en)
|
2002-08-06 |
2005-12-01 |
Idenix Pharmaceuticals Inc |
Crystalline and amorphous forms of beta-L-2'-deoxythymidine
|
US20050043329A1
(en)
*
|
2002-09-06 |
2005-02-24 |
Shlomit Wizel |
Crystalline forms of valacyclovir hydrochloride
|
BR0314259A
(pt)
*
|
2002-09-13 |
2005-07-26 |
Idenix Cayman Ltd |
ß-l-2'-desoxinucleosìdeos para o tratamento de cepas de hbv resistentes e terapias combinadas
|
ES2270172T3
(es)
*
|
2002-10-16 |
2007-04-01 |
Teva Pharmaceutical Industries Ltd. |
Procedimiento para reducir alcoholes residuales en hidrocloruro de valaciclovir cristalino.
|
US20050059684A1
(en)
*
|
2002-10-16 |
2005-03-17 |
Ben-Zion Dolitzky |
Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
|
CN1319972C
(zh)
*
|
2002-10-16 |
2007-06-06 |
特瓦制药工业有限公司 |
在盐酸伐昔洛韦结晶中减少残留醇类物质的方法
|
MXPA05005192A
(es)
|
2002-11-15 |
2005-09-08 |
Idenix Cayman Ltd |
Nucleosidos ramificados en la posicion 2' y mutacion de flaviviridae.
|
TWI332507B
(en)
*
|
2002-11-19 |
2010-11-01 |
Hoffmann La Roche |
Antiviral nucleoside derivatives
|
WO2004052892A1
(en)
*
|
2002-12-09 |
2004-06-24 |
Texcontor Etablissement |
Anhydrous crystalline form of valacyclovir hydrochloride
|
EP1572710A2
(de)
*
|
2002-12-10 |
2005-09-14 |
F. Hoffmann-La Roche Ag |
Antivirale nukleosidderivate
|
CA2509687C
(en)
|
2002-12-12 |
2012-08-14 |
Idenix (Cayman) Limited |
Process for the production of 2'-branched nucleosides
|
CA2511616A1
(en)
*
|
2002-12-23 |
2004-07-15 |
Idenix (Cayman) Limited |
Process for the production of 3'-nucleoside prodrugs
|
AU2004206821C1
(en)
|
2003-01-14 |
2009-10-01 |
Gilead Sciences, Inc. |
Compositions and methods for combination antiviral therapy
|
KR20060008297A
(ko)
*
|
2003-03-20 |
2006-01-26 |
마이크로 바이올로지카 퀴미카 이 파마슈티카 리미티드 |
2'-데옥시-β-L-뉴클레오시드의 제조방법
|
US7595390B2
(en)
*
|
2003-04-28 |
2009-09-29 |
Novartis Ag |
Industrially scalable nucleoside synthesis
|
AU2003232719A1
(en)
*
|
2003-05-30 |
2005-01-21 |
Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. |
Novel crystalline forms of valacyclovir hydrochloride
|
CN100503628C
(zh)
|
2003-05-30 |
2009-06-24 |
法莫赛特股份有限公司 |
修饰的氟化核苷类似物
|
TW200510414A
(en)
|
2003-06-02 |
2005-03-16 |
Teva Pharma |
Novel crystalline forms of valacyclovir hydrochloride
|
RU2361875C2
(ru)
*
|
2003-06-30 |
2009-07-20 |
Айденикс (Кайман) Лимитед |
СИНТЕЗ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
|
US20050025839A1
(en)
*
|
2003-07-28 |
2005-02-03 |
Polli James Edward |
Formulation approach to enhance transporter-mediated drug uptake
|
US20050137141A1
(en)
*
|
2003-10-24 |
2005-06-23 |
John Hilfinger |
Prodrug composition
|
US20070167353A1
(en)
*
|
2003-10-24 |
2007-07-19 |
John Hilfinger |
Prodrug composition
|
US7253175B2
(en)
*
|
2003-11-13 |
2007-08-07 |
Barnet Liberman |
Method for treating athlete's foot
|
WO2005107742A1
(en)
|
2004-05-05 |
2005-11-17 |
Yale University |
Novel antiviral helioxanthin analogs
|
WO2006000922A2
(en)
*
|
2004-06-23 |
2006-01-05 |
Idenix (Cayman) Limited |
5-aza-7-deazapurine derivatives for treating infections with flaviviridae
|
CN101023094B
(zh)
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
JP2007513074A
(ja)
*
|
2004-09-04 |
2007-05-24 |
テバ ファーマシューティカル インダストリーズ リミティド |
単離されたバラシクロビル不純物、バラシクロビル不純物の調製方法および参照標準としての使用
|
KR101177590B1
(ko)
|
2004-09-14 |
2012-08-27 |
파마셋 인코포레이티드 |
2'-플루오로-2'-알킬 치환되거나 또는 다른 선택적으로치환된 리보퓨라노실 피리미딘 및 퓨린 및 그 유도체의제조
|
US20060178512A1
(en)
*
|
2005-02-04 |
2006-08-10 |
Cheruthur Govindan |
Method for preparing amino acid esters of nucleoside analogues
|
ATE546451T1
(de)
|
2005-05-25 |
2012-03-15 |
Lilly Co Eli |
Cyclopropancarbonsäureester von acyclovir
|
TWI375560B
(en)
*
|
2005-06-13 |
2012-11-01 |
Gilead Sciences Inc |
Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
|
TWI471145B
(zh)
|
2005-06-13 |
2015-02-01 |
Bristol Myers Squibb & Gilead Sciences Llc |
單一式藥學劑量型
|
EP1746098A1
(de)
*
|
2005-07-21 |
2007-01-24 |
SOLMAG S.p.A. |
Valacyclovir Polymorphe und Verfahren zu deren Herstellung
|
US20070112193A1
(en)
*
|
2005-11-14 |
2007-05-17 |
Khunt Mayur D |
Valacyclovir process
|
ES2422290T3
(es)
|
2005-12-23 |
2013-09-10 |
Idenix Pharmaceuticals Inc |
Procedimiento para preparar un producto intermedio sintético para la preparación de nucleósidos ramificados
|
GB0605344D0
(en)
*
|
2006-03-17 |
2006-04-26 |
Pliva Istrazivanje I Razvoj D |
Pharmaceutically acceptable salts and polymorphic forms
|
KR100890463B1
(ko)
|
2006-09-19 |
2009-03-26 |
성균관대학교산학협력단 |
동물 세포 감염 바이러스에 대한 항바이러스제
|
US20080167325A1
(en)
*
|
2006-12-27 |
2008-07-10 |
Bs Praveen Kumar |
Valacyclovir compositions
|
CA2675134A1
(en)
*
|
2007-01-12 |
2008-07-24 |
Biomarin Pharmaceutical Inc. |
Pterin analogs
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
US20080281099A1
(en)
*
|
2007-05-07 |
2008-11-13 |
Mayur Devjibhai Khunt |
Process for purifying valacyclovir hydrochloride and intermediates thereof
|
US20090076039A1
(en)
*
|
2007-09-14 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched valacyclovir
|
EP2224927B1
(de)
*
|
2008-01-03 |
2014-08-20 |
BioMarin Pharmaceutical Inc. |
Pterin-analogon zur behandlung eines auf bh4 ansprechenden zustands
|
US20110059921A1
(en)
*
|
2008-03-27 |
2011-03-10 |
Ektar Therapeutics |
Oligomer-Nitrogenous Base Conjugates
|
TW200946541A
(en)
*
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
TW201031675A
(en)
|
2008-12-23 |
2010-09-01 |
Pharmasset Inc |
Synthesis of purine nucleosides
|
AU2009329867B2
(en)
|
2008-12-23 |
2015-01-29 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
US8551973B2
(en)
*
|
2008-12-23 |
2013-10-08 |
Gilead Pharmasset Llc |
Nucleoside analogs
|
TWI576352B
(zh)
*
|
2009-05-20 |
2017-04-01 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
HUE026235T2
(en)
|
2010-03-31 |
2016-06-28 |
Gilead Pharmasset Llc |
Crystalline (S) -isopropyl 2 - (((S) - (((2R, 3R, 4R, 5R) -5- (2,4-dioxo-3,4-dihydropyrimidin-1 (2H) -IL) - 4-Fluoro-3-hydroxy-4-methyltetrahydrofuran-2-IL) methoxy) (phenoxy) phosphoryl) amino) propanoate
|
US8563530B2
(en)
|
2010-03-31 |
2013-10-22 |
Gilead Pharmassel LLC |
Purine nucleoside phosphoramidate
|
TW201242974A
(en)
|
2010-11-30 |
2012-11-01 |
Gilead Pharmasset Llc |
Compounds
|
CN102584825B
(zh)
*
|
2011-01-17 |
2014-04-02 |
四川科伦药物研究有限公司 |
一种合成盐酸伐昔洛韦的方法
|
EP2852592A4
(de)
*
|
2011-11-25 |
2015-12-23 |
Piramal Entpr Ltd |
Verfahren zur herstellung von valacyclovir-hydrochlorid
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
US20140100238A1
(en)
|
2012-10-04 |
2014-04-10 |
Ohio State University |
Method of diagnosing and treating epstein barr virus-based myalgic encephalomyelitis chronic fatigue syndrome patients
|
TW201429475A
(zh)
*
|
2013-01-29 |
2014-08-01 |
Li-Ly Hsiao |
使用抗病毒藥治療末稍神經病變之疾病
|
US20140213600A1
(en)
*
|
2013-01-29 |
2014-07-31 |
Lily Hsiao |
Medicament for treating peripheral neuropathies
|
MX2016002185A
(es)
|
2013-08-27 |
2016-06-06 |
Gilead Pharmasset Llc |
Formulacion combinada de dos compuestos antivirales.
|